O. I. Plaksina
Research Subjects
Research Interests
O. I. Plaksina has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- E. E. Schiller
Podolsk Children Hospital
2 shared publications - A. N. Kazakova
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
1 shared publication - Aleksandr Mikhailovich Popov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 1 Samory Mashela St., Moscow 117198, Russia
1 shared publication - Alexander Karachunsky
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
1 shared publication - Alexey Aleksandrovich Maschan
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation
1 shared publication - Alexey Shamin
N.N. Ivanova Samara Regional Children›s Clinical Hospital
1 shared publication
Latest Publications
- Open Access
- 7 November 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (3) , 289-302
Prognostic factors and long-term treatment outcomes in children with standard-risk acute lymphoblastic leukemia enrolled in the ALL-MB 2008 protocol: a retrospective analysis of 1,702 patients
Introduction . Within the ALL-MB 2008 protocol, the standard-risk group (SRG) was signifi cantly modifi ed, necessitating a detailed study of long-term treatment outcomes. Data analysis of 1,702 newly diagnosed patients allows for evaluating the reproducibility of high survival rates and identifying factors that infl uence the risk of relapse in this cohort. Aim: to evaluate long-term treatment outcomes and identify independent prognostic factors in children with acute lymphoblastic leukemia (ALL) stratified into the SRG of the ALL-MB 2008 protocol. Materials and Methods. A retrospective analysis of data from 1,702 patients (93.5 % of SRG; aged 1–18 years) included in the multicenter ALL-MB 2008 study (2008–2014, 46 participating clinics) was conducted. Survival rates were calculated using the Kaplan–Meier method, the cumulative incidence of relapse (CIR) was estimated using the competing risks method, and multivariate analysis was performed using Cox regression. Database closing date: 01.06.2021, with a median follow-up of 8.7 years. Results . Complete remission (CR) was achieved in 98.5 % of patients. The 12-year event-free survival (EFS) was 86.8 ± 0.8 %, overall survival (OS) was 91.0 ± 0.7 %, the cumulative incidence of relapse (CIR) was 9.0 ± 0.7 %, and treatment-related mortality (TRM) was 4.1 ± 0.5 %. A slow response on day 15 of induction (≥10 % blast cells in the bone marrow [BM]) was associated with a decrease in EFS (78.1 % vs. 89.2 %; p < 0.0001) and an increase in CIR (17.0 % vs. 7.5 %; p < 0.0001). Patients aged ≥10 years had significantly worse EFS (77.5 % vs. 88.3 %; p < 0.0001) and a higher CIR level (18.3 % vs. 7.4 %; p < 0.0001). The presence of the t(12;21)/ETV6::RUNX1 was associated with the most favorable prognosis (EFS 91.7 %). According to the Cox multivariate analysis, independent predictors of unfavorable outcomes were age ≥ 10 years (HR 2.15; 95 % CI 1.49–3.10; p < 0.001) and a slow morphological response on day 15 of induction (HR 1.85; 95 % CI 1.25–2.70; p = 0.002). Conclusion . The outcomes of the ALL-MB 2008 protocol for the standard-risk group are comparable to data from leading international cooperative groups, despite a signifi cant reduction in the intensive chemotherapy phase: omission of high-dose methotrexate and cyclophosphamide, a substantial reduction in the cumulative dose of anthracyclines, and their complete elimination in one-third of patients. Age and early response rate justify further differentiation of therapeutic approaches within the standard-risk group.
- 7 November 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (3) , 289-302
Open AccessPrognostic factors and long-term treatment outcomes in children with standard-risk acute lymphoblastic leukemia enrolled in the ALL-MB 2008 protocol: a retrospective analysis of 1,702 patients
Introduction . Within the ALL-MB 2008 protocol, the standard-risk group (SRG) was signifi cantly modifi ed, necessitating a detailed study of long-term treatment outcomes. Data analysis of 1,702 newly diagnosed patients allows for evaluating the reproducibility of high survival rates and identifying factors that infl uence the risk of relapse in this cohort. Aim: to evaluate long-term treatment outcomes and identify independent prognostic factors in children with acute lymphoblastic leukemia (ALL) stratified into the SRG of the ALL-MB 2008 protocol. Materials and Methods. A retrospective analysis of data from 1,702 patients (93.5 % of SRG; aged 1–18 years) included in the multicenter ALL-MB 2008 study (2008–2014, 46 participating clinics) was conducted. Survival rates were calculated using the Kaplan–Meier method, the cumulative incidence of relapse (CIR) was estimated using the competing risks method, and multivariate analysis was performed using Cox regression. Database closing date: 01.06.2021, with a median follow-up of 8.7 years. Results . Complete remission (CR) was achieved in 98.5 % of patients. The 12-year event-free survival (EFS) was 86.8 ± 0.8 %, overall survival (OS) was 91.0 ± 0.7 %, the cumulative incidence of relapse (CIR) was 9.0 ± 0.7 %, and treatment-related mortality (TRM) was 4.1 ± 0.5 %. A slow response on day 15 of induction (≥10 % blast cells in the bone marrow [BM]) was associated with a decrease in EFS (78.1 % vs. 89.2 %; p < 0.0001) and an increase in CIR (17.0 % vs. 7.5 %; p < 0.0001). Patients aged ≥10 years had significantly worse EFS (77.5 % vs. 88.3 %; p < 0.0001) and a higher CIR level (18.3 % vs. 7.4 %; p < 0.0001). The presence of the t(12;21)/ETV6::RUNX1 was associated with the most favorable prognosis (EFS 91.7 %). According to the Cox multivariate analysis, independent predictors of unfavorable outcomes were age ≥ 10 years (HR 2.15; 95 % CI 1.49–3.10; p < 0.001) and a slow morphological response on day 15 of induction (HR 1.85; 95 % CI 1.25–2.70; p = 0.002). Conclusion . The outcomes of the ALL-MB 2008 protocol for the standard-risk group are comparable to data from leading international cooperative groups, despite a signifi cant reduction in the intensive chemotherapy phase: omission of high-dose methotrexate and cyclophosphamide, a substantial reduction in the cumulative dose of anthracyclines, and their complete elimination in one-third of patients. Age and early response rate justify further differentiation of therapeutic approaches within the standard-risk group.
- Open Access
- 20 December 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (4) , 96-101
The use of emicizumab in children with hemophilia A without inhibitors in the real-world clinical setting
In our country, the use of emicizumab in children with hemophilia A without inhibitors (HA) in the real-world clinical setting is limited and is available only as few individual case reports. Our aim was to evaluate the effectiveness and safety of the prophylactic use of emicizumab in children with severe HA in the real-world clinical setting. We conducted a retrospective analysis of medical records of children with HA who had received emicizumab at 9 centers based in the Russian Federation. We assessed the annualized bleeding rate (ABR), annualized spontaneous bleeding rate (ASBR), annualized joint bleeding rate (AJBR), annualized bleeding rate for bleeding episodes that required additional treatment with FVIII concentrate (ABRRT) and the number of hospital admissions for bleeding both before and after the treatment with emicizumab, as well as the occurrence and severity of adverse events during the therapy. Ethics committee approval was not required for this study because it involved the use of aggregated retrospective data from routine clinical practice that were fully anonymized. Two emicizumab administration regimens were compared with regard to their effectiveness. Before the treatment with emicizumab, ABR was 5.38 (95% confidence interval (CI) 3.90–7.64), ASBR – 4.16 (95% CI 2.99–5.94), AJBR – 2.7 (95% CI 1.87–4.03), and ABRRT – 4.8 (95% CI 3.37–7.08). After the initiation of the treatment with emicizumab, the bleeding rate plummeted: ABR decreased by 93.9% (95% CI 88.8–96.7), ASBR – by 96.9% (95% CI 93.1–98.6), AJBR – by 96.1% (95% CI 90.4–98.4%) and ABRRT – by 95.1% (95% CI 90.0–97.6). During the treatment with emicizumab, the rate of bleeding episodes that required hospital admission decreased from 1.58 (95% CI 0.98–2.68) to 0.04 (0.01–0.10), which amounted to 97.6% (95% CI 91.1–99.4). The median follow-up time for the patients treated with emicizumab was 15.5 months (range 9–29 months). When comparing the annualized bleeding rates in the groups of the patients who were preventively treated with emicizumab at doses of 3 mg/kg (administered once every 2 weeks) and 1.5 mg/kg (once per week), we didn't find any statistically significant differences. In the real-world clinical setting, the use of emicizumab in the children with HA led to a significant reduction in all bleeding episodes (by more than 90%), regardless of the administration regimen.
- 20 December 2023
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 22 (4) , 96-101
Open AccessThe use of emicizumab in children with hemophilia A without inhibitors in the real-world clinical setting
In our country, the use of emicizumab in children with hemophilia A without inhibitors (HA) in the real-world clinical setting is limited and is available only as few individual case reports. Our aim was to evaluate the effectiveness and safety of the prophylactic use of emicizumab in children with severe HA in the real-world clinical setting. We conducted a retrospective analysis of medical records of children with HA who had received emicizumab at 9 centers based in the Russian Federation. We assessed the annualized bleeding rate (ABR), annualized spontaneous bleeding rate (ASBR), annualized joint bleeding rate (AJBR), annualized bleeding rate for bleeding episodes that required additional treatment with FVIII concentrate (ABRRT) and the number of hospital admissions for bleeding both before and after the treatment with emicizumab, as well as the occurrence and severity of adverse events during the therapy. Ethics committee approval was not required for this study because it involved the use of aggregated retrospective data from routine clinical practice that were fully anonymized. Two emicizumab administration regimens were compared with regard to their effectiveness. Before the treatment with emicizumab, ABR was 5.38 (95% confidence interval (CI) 3.90–7.64), ASBR – 4.16 (95% CI 2.99–5.94), AJBR – 2.7 (95% CI 1.87–4.03), and ABRRT – 4.8 (95% CI 3.37–7.08). After the initiation of the treatment with emicizumab, the bleeding rate plummeted: ABR decreased by 93.9% (95% CI 88.8–96.7), ASBR – by 96.9% (95% CI 93.1–98.6), AJBR – by 96.1% (95% CI 90.4–98.4%) and ABRRT – by 95.1% (95% CI 90.0–97.6). During the treatment with emicizumab, the rate of bleeding episodes that required hospital admission decreased from 1.58 (95% CI 0.98–2.68) to 0.04 (0.01–0.10), which amounted to 97.6% (95% CI 91.1–99.4). The median follow-up time for the patients treated with emicizumab was 15.5 months (range 9–29 months). When comparing the annualized bleeding rates in the groups of the patients who were preventively treated with emicizumab at doses of 3 mg/kg (administered once every 2 weeks) and 1.5 mg/kg (once per week), we didn't find any statistically significant differences. In the real-world clinical setting, the use of emicizumab in the children with HA led to a significant reduction in all bleeding episodes (by more than 90%), regardless of the administration regimen.
- Open Access
- 16 March 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (6) , 953-962
Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia
We compared the efficacy and safety of eltrombopag (ELTR) combined with immunosuppressive therapy (IST) and IST alone in treatment-naïve children with severe (SAA) and very severe (vSAA) aplastic anemia. Ninety-eight pediatric patients were randomized to receive horse antithymocyte globulin (hATG) and cyclosporin A (CsA) with (n = 49) or without (n = 49) ELTR. The primary endpoint was the overall response rate (ORR) at 4 months. After 4 months, nonresponders were crossed over to the alternative group. In all patients, the ORR in ELTR + IST and IST groups was similar (65% vs 53%; P = .218); however, the complete response (CR) rate was significantly higher in the ELTR + IST group (31% vs 12%; P = .027). In severity subgroups, the ORR was 89% vs 57% (P = .028) in favor of IST + ELTR in SAA, but it did not differ in patients with vSAA (52% vs 50%; P = .902). At 6 months after the crossover, 61% of initial ELTR(−) patients achieved a response compared with 17% of initial ELTR(+) patients (P = .016). No significant difference in ELTR + IST and IST groups was observed in the 3-year overall survival (OS) (89% vs 91%; P = .673) or the 3-year event-free survival (EFS) (53% vs 41%; P = .326). There was no unexpected toxicity related to ELTR. Adding ELTR to standard IST was well tolerated and increased the CR rate. The greatest benefit from ELTR combined with IST was observed in patients with SAA but not in those with vSAA. The second course of IST resulted in a high ORR in initial ELTR(−) patients who added ELTR and had limited efficacy among patients who received ELTR upfront. This trial was registered at Clinicaltrials.gov as #NCT03413306.
- 16 March 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (6) , 953-962
Open AccessEfficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia
We compared the efficacy and safety of eltrombopag (ELTR) combined with immunosuppressive therapy (IST) and IST alone in treatment-naïve children with severe (SAA) and very severe (vSAA) aplastic anemia. Ninety-eight pediatric patients were randomized to receive horse antithymocyte globulin (hATG) and cyclosporin A (CsA) with (n = 49) or without (n = 49) ELTR. The primary endpoint was the overall response rate (ORR) at 4 months. After 4 months, nonresponders were crossed over to the alternative group. In all patients, the ORR in ELTR + IST and IST groups was similar (65% vs 53%; P = .218); however, the complete response (CR) rate was significantly higher in the ELTR + IST group (31% vs 12%; P = .027). In severity subgroups, the ORR was 89% vs 57% (P = .028) in favor of IST + ELTR in SAA, but it did not differ in patients with vSAA (52% vs 50%; P = .902). At 6 months after the crossover, 61% of initial ELTR(−) patients achieved a response compared with 17% of initial ELTR(+) patients (P = .016). No significant difference in ELTR + IST and IST groups was observed in the 3-year overall survival (OS) (89% vs 91%; P = .673) or the 3-year event-free survival (EFS) (53% vs 41%; P = .326). There was no unexpected toxicity related to ELTR. Adding ELTR to standard IST was well tolerated and increased the CR rate. The greatest benefit from ELTR combined with IST was observed in patients with SAA but not in those with vSAA. The second course of IST resulted in a high ORR in initial ELTR(−) patients who added ELTR and had limited efficacy among patients who received ELTR upfront. This trial was registered at Clinicaltrials.gov as #NCT03413306.
- 13 December 2021
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 100 (6)
EFFICACY AND SAFETY OF MOROCTOCOG ALFA IN AN OPEN, MULTICENTER, PROSPECTIVE, CLINICAL STUDY IN CHILDREN 2 TO 6 YEARS OF AGE WITH SEVERE HEMOPHILIA A
The purpose of the study was to assess the efficacy, safety and pharmacokinetics of the moroctocog alfa (Octofactor) in children aged 2-6 with haemophilia A. Materials and methods of research : six patients between 2 and 6 years of age (average age 4.3±0.8 years) were included in the open multicenter prospective clinical trial. The efficacy of the drug was assessed against the background of the introduction of 30±10 IU/kg every 2–3 days, the safety was assessed by the frequency and causality of adverse reactions. Results: 7 post-traumatic bleeding was registered. The average prophylactic dose of the drug is 37.84±7.13 IU/kg. The dose of the drug for stopping bleeding was 1000 IU. 2 adverse events have been reported that are not related to moroсtocog alfa. Conclusion: the obtained data indicate the efficacy and safety of moroсtocog alfa in the study group of patients.
- 13 December 2021
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 100 (6)
EFFICACY AND SAFETY OF MOROCTOCOG ALFA IN AN OPEN, MULTICENTER, PROSPECTIVE, CLINICAL STUDY IN CHILDREN 2 TO 6 YEARS OF AGE WITH SEVERE HEMOPHILIA A
The purpose of the study was to assess the efficacy, safety and pharmacokinetics of the moroctocog alfa (Octofactor) in children aged 2-6 with haemophilia A. Materials and methods of research : six patients between 2 and 6 years of age (average age 4.3±0.8 years) were included in the open multicenter prospective clinical trial. The efficacy of the drug was assessed against the background of the introduction of 30±10 IU/kg every 2–3 days, the safety was assessed by the frequency and causality of adverse reactions. Results: 7 post-traumatic bleeding was registered. The average prophylactic dose of the drug is 37.84±7.13 IU/kg. The dose of the drug for stopping bleeding was 1000 IU. 2 adverse events have been reported that are not related to moroсtocog alfa. Conclusion: the obtained data indicate the efficacy and safety of moroсtocog alfa in the study group of patients.